Skip to main content
Top

20-08-2021 | Empagliflozin | News

approvalsWatch

Empagliflozin receives FDA approval for use in adults with heart failure

Author: Eleanor McDermid

print
PRINT
insite
SEARCH

medwireNews: The sodium-glucose cotransporter 2 inhibitor empagliflozin may now be used to reduce the risk for cardiovascular death and heart failure hospitalization in adults with heart failure and reduced ejection fraction in the USA.

Its other approved uses are to reduce glucose levels in adults with type 2 diabetes and to reduce the risk for cardiovascular death in those who also have established cardiovascular disease.

FDA approval for the expanded indication follows the 2020 publication of the EMPEROR-Reduced trial, which found a significant 25% reduction in the risk for death from cardiovascular causes or hospitalization for heart failure with empagliflozin versus placebo in this patient group.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

print
PRINT

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »